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Background: In children born small for gestational age (SGA) with persistent short stature, 
2 years of gonadotropin-releasing hormone analogue (GnRHa), in addition to long-term growth 
hormone (GH) treatment, can improve adult height. We assessed safety on metabolic and bone 
health of GnRHa/GH treatment during 5 years after cessation of GH.
Methods: A total of 363 young adults born SGA, previously treated with combined GnRHa/
GH or GH-only, were followed for 5 years after attainment of adult height at GH cessation 
and 2 and 5 years thereafter. Data at 5 years after GH cessation, at age 21 years, were also 
compared with 145 age-matched adults born appropriate for gestational age (AGA). Frequently 
sampled intravenous glucose tolerance (FSIGT) tests were used to assess insulin sensitivity, acute 
insulin response, and β-cell function. Body composition and bone mineral density (BMD) was 
determined by dual-energy x-ray absorptiometry (DXA) scans.
Findings: In the GnRHa/GH and GH-only groups, fat mass increased during the 5 years after GH 
cessation, but the changes in FSIGT results, body composition, blood pressure, serum lipid levels, and 
BMD were similar in both groups. At age 21 years, the GnRHa/GH group had similar fat mass, FSIGT 
results, blood pressure, serum lipid levels and BMD-total body as the GH-only group and the AGA 
control group, a higher BMD-lumbar spine and lower lean body mass than the AGA control group.
Interpretation: This study during 5 years after GH cessation shows that addition of 2 years of GnRHa 
treatment to long-term GH treatment of children short in stature born SGA has no unfavorable 
effects on metabolic and bone health in early adulthood. (J Clin Endocrinol Metab 105: 1–11, 2020)
Clinical trial registration: ISRCTN96883876, ISRCTN65230311 and ISRCTN18062389.
Key Words:  SGA, insulin sensitivity, growth hormone, pubertal suppression, metabolic health, 
GnRHa treatment
In children born small for gestational age (SGA) with persistent short stature, treatment with growth 
hormone (GH) leads to adult height (AH) improve-
ment (1-3). The Dutch SGA study has shown that 
postponement of puberty with a gonadotropin-releasing 
hormone analogue (GnRHa) for 2 years at the start of 
puberty because of an expected AH <−2.5 standard 
Abbreviations: AGA, appropriate for gestational age; AH, adult height; AIR, acute in-
sulin response; BMADLS, bone mineral apparent density lumbar spine; BMD, bone min-
eral density; BMDLS, BMD of lumbar spine; BMDTB, BMD of total body; BMI, body mass 
index; CPP, central precocious puberty; DBP, diastolic blood pressure; DI, disposition 
index; DXA, dual-energy x-ray absorptiometry; FM, fat mass; FSIGT, frequently sampled 
intravenous glucose tolerance; GH, growth hormone; GnRHa, gonadotropin-releasing 
hormone analogue; HDLc, high-density lipoprotein cholesterol; LBM, lean body mass; 
LDLc, low-density lipoprotein cholesterol; LF, limb fat; SBP, systolic blood pressure; SDS, 
standard deviation score; SGA, small for gestational age; Sg, glucose effectiveness; Si, 
insulin sensitivity; TC, total cholesterol; TF, trunk fat; TG, triglyceride.
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deviation score (SDS) can improve AH in children born 
SGA who start GH treatment in early puberty (4).
In patients with central precocious puberty (CPP), a 
decrease in insulin sensitivity, expressed in the homeo-
static model assessment of insulin resistance, was de-
scribed during GnRHa treatment (5-8). Gain in weight 
and fat mass during treatment with GnRHa was re-
ported, potentially causing obesity in adulthood (9-13). 
In studies with patients with CPP, a decrease in bone 
turnover and bone mineral density (BMD) was ob-
served during GnRHa treatment (12, 14-16). However, 
studies were performed retrospectively in children 
with CPP, and most studies evaluated the changes only 
during GnRHa treatment. Our study group has shown 
no negative effects of 2 years of GnRHa treatment in 
addition to GH treatment until AH attainment (17-19). 
Studies on long-term safety of postponing puberty with 
GnRHa treatment regarding metabolic health and bone 
mineralization in young adults born SGA following GH 
cessation at adult height attainment are lacking.
We performed a longitudinal study during the 5 years 
after GH cessation in young adults who were treated 
with GH until AH, either with or without an additional 
2 years of GnRHa after onset of puberty. The primary 
objective of the study was to assess insulin sensitivity, 
β-cell function, body composition, blood pressure, serum 
lipid levels, and BMD during the 5 years after GH cessa-
tion. We hypothesized that postponement of puberty by 
2 years of GnRHa treatment in GH-treated young adults 
born SGA would not negatively influence these outcome 
measures in early adulthood compared with GH treat-
ment only and would result in a similar metabolic and 
cardiovascular health profile and BMD in both treatment 
groups. Our secondary objective was to compare both 
treatment groups at 5 years after GH cessation with a 
healthy young adult cohort. We hypothesized that treat-
ment with either GnRHa/GH or GH-only would result in 
a similar metabolic and cardiovascular health and similar 
BMD compared with healthy young adults born appro-
priate for gestational age (AGA).
Method
Participants
The study group consisted of 363 young adults born 
SGA who had participated in 1 of 3 Dutch SGA trials 
(ISRCTN96883876 [registered January 27, 2006], 
ISRCTN65230311 [registered September 17, 2006], and 
ISRCTN18062389 [registered December 20, 2005]). SGA 
was defined as birth weight or birth length below –2 SDS 
for gestational age, with a height at the start of GH treat-
ment below –2.5 SDS and no endocrine, metabolic, or 
chronic disorders. GH treatment was started before puberty 
or in early puberty and continued until attainment of AH. 
Participants received GnRHa treatment for 2 years in add-
ition to GH treatment (n = 112; GnRHa/GH group) or only 
GH treatment (n = 251; GH group). Two years of GnRHa 
treatment was prescribed when the expected AH was less 
than –2.5 SDS at start of puberty, based on Dutch refer-
ences (20). A subgroup (n = 95) was randomly assigned to 
treatment with either GH 1 or 2  mg/m2/day (∼ 0.033 or 
0.067  mg/kg/d) after stratification for sex, pubertal stage, 
and parental height.
Data at 5  years after GH cessation were compared with 
those of 145 young adults born AGA (birth length > –1 SDS) 
with a normal stature (>–1 SDS) and aged 18 to 24 years (21, 
22). These healthy young adults were recruited from different 
schools to participate as AGA controls.
The Medical Ethics Committee of the Erasmus University 
Medical Centre approved the studies. Due to ethical consid-
erations, the Medical Ethics Committee did not allow a ran-
domized untreated SGA group with short stature until adult 
height. We obtained written informed consent from all par-
ticipants and from their parents or guardians if they were 
younger than age 18 years.
Measurements
At start, every 3 months during GH treatment and at AH, 
height was measured to the nearest 0.1 cm using a Harpenden 
stadiometer (Holtain, Ltd. Crymmyth, UK). Height was trans-
formed into SDS for sex and chronological age according to 
Dutch references, using Growth Analyser Research Calculation 
Tools (Growth Analyser B.V., Rotterdam, The Netherlands). 
AH SDS was calculated using references for Dutch adults, 
aged 18 years (20). Weight was measured to the nearest 0.1 kg 
(Servo Balance KA-20-150S). Body mass index (BMI) was ex-
pressed as SDS adjusted for sex and chronological age, ac-
cording to Dutch references (20).
Insulin sensitivity and β-cell function
Glucose homeostasis was assessed by a frequently sam-
pled intravenous glucose tolerance test (FSIGT) with tol-
butamide after an overnight fast (Cutfield WS et al, 1990). 
Insulin sensitivity (Si), glucose effectiveness (Sg), acute in-
sulin response (AIR), and disposition index (DI) were cal-
culated using Bergman’s MINMOD Millennium software 
(Boston RC et  al, 2003). Si quantifies the capacity of in-
sulin to stimulate glucose disposal, and Sg reflects the cap-
acity of glucose to mediate its disposal. AIR is an estimate 
of insulin secretory capacity, measured as the area under the 
curve from 0 to 10 minutes and corrected for baseline in-
sulin levels. The DI equals AIR x Si and indicates the β-cell 
function.
Body composition and bone mineral density 
Total fat mass (FM), lean body mass (LBM), trunk fat 
(TF), limb fat (LF), bone mineral density of the total body 
(BMDTB) and the lumbar spine (BMDLS) were measured by 
a dual-energy x-ray absorptiometry (DXA) scan on the same 
machine (Lunar Prodigy, GE Healthcare, Chalfont St Giles, 
UK). Daily quality assurance was performed. The intra-assay 
coefficient of variation was 0.41% to 0.88% for fat tissue, 
1.57% to 4.49% for LBM, 0.64% for BMDTB, and 1.04% for 
the BMDLS (23, 24).
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In all participants with short stature, true BMDLS is 
underestimated by the areal presentation and should be 
corrected for bone size by calculating the bone mineral ap-
parent density (BMADLS) (25). BMADLS was calculated as 
follows: BMADLS = BMDLS x [4/(π x width)], with the width 
as the mean width of the second to fourth lumbar vertebral 
body. Because BMDTB and BMADLS are dependent on age 
and gender, SDS were calculated, based on age- and gender-
matched reference values from the Dutch population (26, 
27).
Blood pressure
After 10 minutes of rest, diastolic blood pressure (DBP) and 
systolic blood pressure (SBP) were measured repeatedly during 
half an hour in supine position, using the nondominant arm 
with an automated device (Accutorr Plus, Datascope Corp., 
Montvale NJ, USA). The mean of 7 measurements was taken 
for analysis, to reflect resting blood pressure. Blood pressure 
values were adjusted for sex and height. SBP and DBP values 
were expressed in SDS according to sex- and age-matched ref-
erence values (28).
Assays
Fasting glucose levels were determined on an Architect 
ci8200 system (Abbott). Fasting insulin levels were measured 
by IRMA (Medgenix, Biosource Europe) with an intra-assay 
coefficient of variation of 2.1% to 1.5% (6.6-53.3 milligram 
equivalents/L) and interassay coefficient of variation 6.5% to 
6.1% (14.4-100.4 milligram equivalents/L).
Total cholesterol (TC) and triglyceride (TG) were meas-
ured using an automated enzymatic method with the 
CHOD-PAP reagent kit and with the GPO-PAP reagent kit, 
respectively (Roche Diagnostics, Mannheim, Germany). 
High-density lipoprotein cholesterol (HDLc) was meas-
ured using a homogeneous enzymatic colorimetric assay 
(Roche Diagnostics). Low-density lipoprotein cholesterol 
(LDLc) was calculated using the Friedewald formula: LDLc 
(mmol/l) = TC − HDLc − 0.45 x TG.
Data analysis
Statistical analyses were performed using SPSS version 25. 
Distribution of variables was determined by the Kolmogorov-
Smirnov test and normal Q-Q-plots. Clinical character-
istics are presented as means (SD); the Student t test was 
used to determine differences between subgroups. Because 
of a skewed distribution, Si, Sg, AIR, and DI were log-
transformed. Longitudinal changes in FSIGT results, body 
composition, blood pressure, serum lipid levels, and BMD 
results were analyzed using repeated measurements analysis, 
with an unstructured covariance matrix. We used sex as a 
covariate for the initial analysis of longitudinal changes in 
FSIGT test results, body composition, lipid levels, and BMD 
results. For longitudinal analyses on blood pressure, we ad-
justed for sex and age. Analysis of covariance was used for 
comparisons between the groups at the age of 21 years, with 
sex as covariate for all variables. Body composition, blood 
pressure, BMDTB, and BMADLS were additionally adjusted 
for height. Results were regarded as statistically significant 
at P < 0.05.
Results
Baseline characteristics
Table 1 shows the clinical characteristics of all par-
ticipants at the start of GH treatment, at AH, and at 
21 years of age (5 years after GH cessation). In total, 
363 participants (112 GnRHa/GH, 251 GH) partici-
pated in the study. Mean (SD) age at start of GnRHa 
treatment was 12.1 (1.0) years in boys and 11.2 (1.1) 
years in girls. In the GnRHa/GH and GH groups, mean 
age at start of GH treatment was 9.7 (3.1) versus 7.4 
(2.8) years (P < 0.001), respectively. At the attainment 
of AH, mean age in boys was 18.1 (0.9) versus 17.4 
(1.2) years (P = 0.004) and 16.4 (1.2) versus 15.7 (0.9) 
years (P < 0.001) in girls, in the GnRHa/GH and GH 
groups, respectively.
At 5 years after GH cessation, mean age was similar 
in the GnRHa/GH and GH group (22.4 [2.1] vs 21.9 
[1.6] years, respectively). The GnRHa/GH group was 
significantly older than the AGA group (20.8 [2.7] 
years). The GnRHa/GH group had a different sex distri-
bution (males 33%) when compared with the GH group 
(males 56%) and AGA group (males 46%) (P = 0.03, 
P = 0.05, respectively).
GnRHa/GH group versus GH-only group during 
5 years after cessation of GH
Insulin sensitivity and β-cell function.  Table 2 and 
Figure 1a show the longitudinal changes in Si, Sg, AIR, 
and DI after GH cessation in the GnRHa/GH and GH 
groups. Changes in Si, Sg, AIR, and DI were similar in 
the GnRHa/GH and GH groups during the 5 years after 
GH cessation (P = 0.39, P = 0.07, P = 0.79, P = 0.92, 
respectively). Additional adjustment for age did not 
change these results.
In the GnRHa/GH group, Si increased significantly 
during the first 2  years after GH cessation, while the 
Sg and AIR decreased significantly (all P  < 0.001). In 
the following 3 years, Si, Sg, and AIR remained similar. 
DI remained similar during the 5 years after GH cessa-
tion. Similarly, in the GH group, during the first 2 years 
after GH cessation. Si increased and both Sg and AIR 
decreased (all P < 0.001). In the following 3 years, Si, 
Sg, and AIR remained similar. DI also remained similar 
during the 5-year follow-up period.
At 5 years after GH cessation, the GnRHa/GH group 
had a similar Si, AIR, and DI and a significantly lower 
Sg (P = 0.049) than the GH group (Table 3). None of the 
participants in the GnRHa/GH group and GH group 
had glucose intolerance or developed type 2 diabetes up 
to 5 years after GH cessation.
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Body composition.  Table 2 and Figure 1b show the 
longitudinal changes in body composition after GH 
cessation in the GnRHa/GH and GH groups, meas-
ured by DXA-scan. Changes in FM, LBM, TF, and LF 
were similar in the GnRHa/GH group and GH group 
during the 5-year follow-up period (P = 0.26, P = 0.08, 
P = 0.24, P = 0.10, respectively). Additional adjustment 
for age did not change the results.
In the GnRHa/GH group, FM, LF, and TF increased 
consistently and significantly during the 5  years after 
GH cessation (all P < 0.001), whereas LBM remained 
similar during this follow-up period. Also, in the GH 
group, FM, LF, and TF increased consistently and sig-
nificantly, while LBM remained similar during this 
5-year follow-up period.
At 5  years after GH cessation, FM, LBM, TF, and 
LF were similar in the GnRHa/GH and GH groups 
(Table 3). Mean (SD) BMI SDS was –0.3 (1.2) in the 
GnRHa/GH group, which was similar in the GH group 
(–0.3 (1.4); P = 0.90).
Blood pressure.  Table 2 and Figure 2a show the lon-
gitudinal changes in SBP and DBP in the GnRHa/GH 
and GH groups. The GnRHa/GH group had higher SBP 
and DBP values at GH cessation, but changes in SBP 
and DBP during the 5  years after GH cessation were 
similar in both groups (P = 0.84, P = 0.43, respectively).
In the GnRHa/GH group, SBP and DBP remained 
similar and within normal range (from 115.6 to 
116.4 mmHg; P = 0.06 and from 68.9 to 70.0 mmHg; 
P = 0.27, respectively) during 5 years after GH cessa-
tion. In the GH group, both SBP and DBP remained 
well within the normal range but increased significantly 
during the 5-year follow-up period (from 112.6 to 
116.0 mmHg and from 64.0 to 66.3 mmHg, respect-
ively, both P < 0.001).
At 5  years after GH cessation, SBP and DBP were 
still well within the normal range in both groups. The 
GnRHa/GH group had similar SBP (119.5 mmHg) and 
higher DBP (71.0 mmHg) when compared with the GH 
group (117.6 and 67.7 mmHg; P = 0.40 and P = 0.01, 
respectively) (Table 3).
Serum lipid levels.  Table 2 and Figure 2b show the 
longitudinal changes in serum lipid levels in the GnRHa/
GH and GH groups. Changes in TC, HDLc, LDLc, and 
Table 1. Baseline characteristics
Study Group Comparison Groups
GnRHa/GH GH AGA
Means (SD) Means (SD) Means (SD)
N 112 251 145
Male/female 37/75a,b 140/111 67/78
Gestational age, weeks 36.8 (3.8) 36.4 (3.7) 36.6 (4.1)
Birth length SDS –2.8 (1.3)b –3.1 (1.5) 0.2 (0.8)
Birth weight SDS –2.2 (1.4)b –2.2 (1.1) 0.3 (1.2)
Age at start GnRHa, years 11.5 (1.2) N/A N/A
Age at start GH, years 9.7 (3.1)a 7.4 (2.8) N/A
BMI at start puberty, SDS –1.0 (1.0) –0.8 (1.0) N/A
At adult height    
Age, years 17.0 (1.3) 16.7 (1.4) N/A
Height SDS –1.7 (0.8) –1.5 (0.8) N/A
BMI SDS –0.2 (1.1) –0.1 (1.0) N/A
SBP SDS 0.2 (0.9)a 0.0 (0.8) N/A
DBP SDS 0.6 (0.7)a 0.1 (0.7) N/A
GH duration, years 7.1 (2.3)a 9.3 (2.6) N/A
BMDTB SDS –0.7 (0.9) –0.5 (1.0) N/A
BMADLS SDS –0.2 (1.2) –0.2 (1.0) N/A
At age 21 years (5 years after GH)    
Male/female 16/35a,b 70/72 67/78
Age, years 22.4 (2.1)b 21.9 (1.6) 20.8 (2.7)
Height SDS –1.5 (0.8)b –1.4 (0.8) 0.3 (0.8)
BMI SDS –0.3 (1.2) –0.3 (1.4) 0.0 (1.1)
BMDTB SDS –0.3 (0.9)
a –0.6 (1.0) –0.3 (0.8)
BMADLS SDS –0.2 (1.1)
a –0.4 (0.8) –0.5 (1.0)
Values are presented as means (SD). 
Abbreviations: AGA, BMADLS, bone mineral apparent density lower spine; BMDTB, BMD of total body; BMI, body mass index; DBP, diastolic blood pressure 
GH, growth hormone; GnRHa, gonadotropin-releasing hormone agonist; N/A, not available; SBP, systolic blood pressure; SD, standard deviation; SDS, SD 
score.
 aP < 0.05 compared with GH.bP < 0.05 compared with AGA.
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TG during the 5 years after GH cessation were similar 
in both groups (P = 0.39, P = 0.71, P = 0.40, P = 0.18, 
respectively). Additional adjustment for age and FM did 
not change these results.
In the GnRHa/GH group, TC, HDLc, and LDLc in-
creased significantly (P < 0.001, P = 0.008, P < 0.001, 
respectively), while TG remained similar during the 
5  years after GH cessation (P  =  0.50). In the GH 
group, TC and LDLc also increased significantly 
(P  <  0.001), but HDLc and TG remained similar 
during this 5-year follow-up period (P  =  0.26, 
P = 0.98, respectively).
At 5 years after GH cessation, the GnRHa/GH and 
GH groups had similar serum lipid levels (TC: P = 0.46; 
HDLc: P = 0.38; LDLc: P = 0.36; TG: P = 0.10).
BMD. Table  2 and Fig. 2c show the longitudinal 
changes in BMDTB SDS and BMADLS SDS in the 
Table 2. Longitudinal data during 5 years after GH cessation
Outcome Study Moment
GnRHa/GH GH
P ValueEMM 95% CI EMM 95% CI
Insulin sensitivity AH 4.963 4.20-5.72 5.008 4.49-5.52 0.391
(mU/L) 2 yrs after AH 7.222 5.53-8.91 8.721 7.37-10.07  
 5 yrs after AH 7.471 5.88-9.06 7.902 6.90-8.90  
Glucose effectiveness AH 0.019 0.018-0.021 0.018 0.017-0.019 0.072
(mg/dL) 2 yrs after AH 0.021 0.019-0.022 0.021 0.020-0.023  
 5 yrs after AH 0.019 0.016-0.022 0.021 0.020-0.023  
Acute insulin response AH 765.1 659.0-871.1 679.7 608.3-751.1 0.794
(mU/L) 2 yrs after AH 639.0 537.9-740.1 570.1 495.3-644.9  
 5 yrs after AH 587.7 473.4-702.1 555.3 480.3-630.2  
Disposition index AH 2815.1 2404-3227 2880.6 2604-3157 0.921
 2 yrs after AH 3131.3 2589-3673 3574.6 3146-4002  
 5 yrs after AH 3248.3 2516-3980 3159.4 2694-3625  
Fat mass (in kg) AH 12.80 11.7-13.9 10.44 9.7-11.2 0.256
 2 yrs after AH 15.35 14.1-16.6 13.29 12.4-14.2  
 5 yrs after AH 17.11 15.5-18.7 15.94 14.9-17.0  
Lean body mass (in kg) AH 40.18 38.4-42.0 43.44 42.2-44.7 0.075
 2 yrs after AH 38.80 37.2-40.4 42.30 41.2-43.4  
 5 yrs after AH 39.66 38.0-41.3 42.38 41.3-43.5  
SBP (mmHg) AH 114.94 112.9-116.9 112.85 111.5-114.2 0.837
 2 yrs after AH 116.01 114.0-118.1 113.90 112.5-115.3  
 5 yrs after AH 117.39 114.8-119.9 116.09 114.5-117.7  
DBP (mmHg) AH 68.87 67.4-70.4 64.03 63.0-65.1 0.426
 2 yrs after AH 69.87 68.4-71.4 65.07 64.1-66.1  
 5 yrs after AH 69.77 67.9-71.6 66.30 65.1-67.5  
TC (mmol/L) AH 4.00 3.9-4.1 3.95 3.9-4.0 0.391
 2 yrs after AH 4.29 4.1-4.5 4.13 4.0-4.3  
 5 yrs after AH 4.46 4.3-4.7 4.30 4.2-4.4  
HDLc (mmol/L) AH 1.45 1.4-1.5 1.42 1.4-1.5 0.724
 2 yrs after AH 1.47 1.4-1.5 1.44 1.4-1.5  
 5 yrs after AH 1.55 1.4-1.7 1.46 1.4-1.5  
LDLc (mmol/L) AH 2.28 2.2-2.4 2.25 2.2-2.3 0.395
 2 yrs after AH 2.58 2.4-2.7 2.45 2.3-2.6  
 5 yrs after AH 2.74 2.6-2.9 2.61 2.5-2.7  
TG (mmol/L) AH 1.02 0.9-1.1 1.02 1.0-1.1 0.184
 2 yrs after AH 1.01 0.9-1.1 0.91 0.8-1.0  
 5 yrs after AH 0.99 0.9-1.1 1.02 1.0-1.1  
BMDTB AH –0.69 –0.92 to –0.47 –0.65 –0.93 to –0.38  
(SDS) 2 yrs after AH –0.54 -0.76 to –0.32 –0.61 –0.88 to –0.34  
 5 yrs after AH –0.47 –0.72 to –0.22 –0.57 –0.88 to –0.27 0.182
BMADLS AH –0.21 –0.42 to –0.00 –0.18 –0.38 to 0.02  
(SDS) 2 yrs after AH –0.23 –0.43 to –0.02 –0.39 –0.58 to –0.20  
 5 yrs after AH –0.26 –0.49 to –0.03 –0.36 –0.58 to –0.14 0.081
Results of repeated measurements analysis, presented as estimated marginal means with 95% CI, and P values for repeated measurements in the 
zero-year to 5-year follow-up. All variables were corrected for sex; blood pressure was additionally adjusted for age. 
P value: difference in change between GnRHa/GH and GH group in outcome variable during 5 years after cessation.Abbreviations: AH, adult height; 
BMADLS, bone mineral apparent density lumbar spine; BMD, bone mineral density; BMDTB, BMD of total body; CI, confidence interval; DBP, diastolic 
blood pressure; EMM, estimated marginal mean; GH, growth hormone; GnRHa, gonadotropin-releasing hormone agonist; HDLc, high-density lipo-
protein cholesterol; LDLc, low-density lipoprotein cholesterol; SBP, systolic blood pressure; SDS, standard deviation score; TC, total cholesterol; TG, 
triglyceride; yrs, years.
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GnRHa/GH and GH groups. Changes in BMDTB SDS 
and BMADLS SDS during the 5  years after GH ces-
sation were similar in both groups (P  =  0.182 and 
P = 0.081, respectively).
In the GnRHa/GH group, BMDTB SDS increased sig-
nificantly (P  =  0.009) and BMADLS remained similar 
(P  =  0.89). In the GH group, both the BMDTB and 
BMADLS remained similar (P = 0.33 and P = 0.85, re-
spectively) during the 5 years after GH cessation.
At 5 years after GH cessation, the GnRHa/GH group 
had a similar BMDTB and BMADLS, compared with the 
GH group (–0.29 vs –0.60 SDS; P = 0.170 and –0.26 vs 
–0.44; P = 0.053, respectively).
GnRHa/GH group versus AGA group at 21 years 
of age
Insulin sensitivity and β-cell function measured 
by FSIGT. The GnRHa/GH group had a similar Si, Sg, 
AIR, and DI as the AGA group (Table 3, Fig. 1a). None 
of the participants of the GnRHa/GH, GH, or AGA 
groups had diabetes mellitus at 21 years of age.
Figure 1. Longitudinal changes during 5 years after GH cessation in FSIGT results (a) and body composition (b). Data are expressed as estimated 
marginal means with the upper limit of the 95% confidence interval, adjusted for sex. Body composition was additionally adjusted for height. P 
values for the comparison between groups at 5 years after GH cessation were depicted if P values < 0.05. Abbreviations: AGA, appropriate for 
gestational age; AH, adult height; AIR, acute insulin response; DI, disposition index; FM, fat mass; GH, growth hormone; GnRHa, gonadotropin-
releasing hormone agonist; LBM, lean body mass; LF, limb fat; SI, insulin sensitivity; TF, trunk fat; yrs, years.
*P value < 0.05 compared with previous visit in GnRHa/GH-treated young adults.
# P value < 0.05 compared with previous visit in GH-treated young adults.
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Body composition. FM, TF, and LF were similar in the 
GnRHa/GH and AGA groups, but LBM was lower in 
the GnRHa/GH group (P = 0.002) (Table 3, Fig. 1b). 
The GnRHa/GH group had a similar mean BMI SDS as 
the AGA group (–0.3 [1.2] vs 0.0 [1.1]; P = 0.08). Only 
1 (0.8%) participant of the GnRHa/GH group had a 
BMI above 2 SDS, which did not significantly differ 
from the GH group (7 participants, 2.5%) and the AGA 
group (4 participants, 2.8%).
Blood pressure. The GH/GnRHa group had similar 
SBP and DBP compared with the AGA group (P = 0.17, 
P = 0.23, respectively) (Table 3, Fig. 2a). The number 
of participants with a high SBP (above 140 mmHg) or 
high DBP (above 90  mmHg) at age 21  years did not 
differ between the GnRHa/GH, GH, and AGA groups. 
High SBP: GnRHa/GH: 2 (3.9%); GH: 5 (3.5%); AGA: 
4 (2.8%) and high DBP: GnRHa/GH: 2 (3.9%); GH: 1 
(0.7%); and AGA: 0 (0%).
Serum lipid levels. The GnRHa/GH group had similar 
serum lipid levels as the AGA group (Table 3, Fig. 2b). 
Additional adjustment for body fat did not change the 
results.
BMD. The GnRHa/GH group had a similar BMDTB 
SDS (P  =  0.60) and a higher BMADLS compared 
with the AGA group (–0.26 vs –0.58 SDS; P = 0.009) 
(Table 3).
Effect of treatment with 2 versus 1 mg GH/m2/day 
at 21 years of age
A subgroup of participants (n = 95) was randomly 
assigned to receive either 2 or 1 mg GH/m2/day from 
start of puberty until GH cessation (data not shown). 
At 5 years after GH cessation, those treated with 2 mg 
GH/m2/day had a significantly higher LBM (P = 0.04) 
than those treated with GH 1  mg GH/m2/day. In the 
participants who had received 2  mg GH/m2/day, FM 
and TF were lower, and LBM was higher compared 
with those who were treated with 1  mg GH/m2/day 
(P = 0.06, P = 0.09, P = 0.07, respectively). FSIGT re-
sults, LF, blood pressure, serum lipid levels, and BMD 
were similar in both GH-dose groups.
Discussion
This longitudinal study during the 5  years after dis-
continuation of GH treatment is currently the longest 
Table 3. Comparison between the groups at age 21 years
GnRHa/GH GH
P Valuea
AGA
P ValuebEMM (95% CI) EMM (95% CI) EMM (95% CI)
Glucose metabolism      
Glucose effectiveness 0.019 (0.017-0.022) 0.021 (0.020-0.023) 0.049 0.018 (0.016-0.020) 0.888
Insulin sensitivity 8.03 (5.9-10.1) 8.01 (6.7-9.3) 0.228 8.585 (7.1-10.1) 0.766
Acute insulin response 509.6 (386.3-633.1) 572.0 (497.1-646.6) 0.373 441.3 (350.4-532.1) 0.885
Disposition indexc 3171.7 (2428-3915) 3217.8 (2768-3667) 0.791 2935 (2388-3483) 0.887
Body composition      
Fat mass (kg) 16.36 (14.0-18.7) 16.76 (15.3-18.3) 0.756 15.61 (14.0-17.3) 0.649
Lean body mass (kg) 44.89 (43.7-46.1) 44.18 (43.42-44.94) 0.283 47.05 (46.2-47.9) 0.008
Trunk fat (kg) 8.19 (6.9-9.5) 8.33 (7.5-9.2) 0.851 7.59 (6.5-9.2) 0.494
Limb fat (kg) 7.60 (6.5-8.7) 7.70 (7.0-8.4) 0.860 7.38 (6.6-8.1) 0.771
Blood pressure      
Systolic (mmHg) 119.5 (116-122) 117.6 (116-120) 0.259 116.6 (11-119) 0.167
Diastolic (mmHg) 71.0 (69-73) 67.7 (66-71) 0.012 69.0 (67-71) 0.226
Serum lipid levels      
TC (mmol/L) 4.40 (4.2-4.6) 4.30 (4.2-4.6) 0.460 4.39 (4.3-4.5) 0.977
HDLc (mmol/L) 1.53 (1.4-1.6) 1.46 (1.4-1.6) 0.382 1.43 (1.4-1.5) 0.117
LDLc (mmol/L) 2.70 (2.5-2.9) 2.59 (2.5-2.7) 0.357 2.56 (2.4-2.7) 0.257
TG (mmol/L) 0.91 (0.8-1.0) 1.03 (1.0-1.2) 0.101 0.98 (0.9-1.1) 0.356
Bone mineral density      
BMDTB (SDS) –0.29 (–0.7 to 0.1) –0.60 (–0.8 to –0.4) 0.170 –0.41 (–0.6 to –0.2) 0.595
BMADLS (SDS) –0.26 (–0.5 to 0.0) –0.44 (–0.6 to –0.3) 0.053 –0.58 (–0.8 to –0.4) 0.009
Results of the ANCOVA analysis between GnRHa/GH, GH, and AGA at 21 years of age. All variables were corrected for sex; body composition and 
bone mineral density were additionally adjusted for height; blood pressure was additionally adjusted for height. Abbreviations: ANCOVA, analysis of 
covariance; AGA, appropriate for gestational age; BMADLS, bone mineral apparent density lumbar spine; BMDTB, BMD of total body; CI, confidence 
interval; EMM, estimated marginal mean; GH, growth hormone; GnRHa, gonadotropin-releasing hormone agonist; HDLc, high-density lipoprotein 
cholesterol; LDLc, low-density lipoprotein cholesterol; SDS, standard deviation score; TC, total cholesterol; TG, triglyceride.
aP value for the comparison between GnRHa/GH-treated and GH-treated young adults born SGA.
b P value for the comparison between GnRHa/GH-treated young adults born SGA and young adults born AGA.
cA measure of β-cell function, calculated as insulin sensitivity × acute insulin response.
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Figure 2. Longitudinal changes during 5 years after GH cessation in blood pressure (a), serum lipid levels (b), and bone mineral density (c). Data 
are expressed as estimated marginal means with the upper limit of the 95% confidence interval, adjusted for sex. P values for the comparison 
between groups at 5 years after GH cessation were depicted if P values < 0.05. Abbreviations: AGA, appropriate for gestational age; AH, 
adult height; BMDTB, bone mineral density of the total body; BMDLS, bone mineral density of the lumbar spine; GH, growth hormone; GnRHa, 
gonadotropin-releasing hormone agonist; HDL, high-density lipoprotein; LDL, low-density lipoprotein; RR, Riva-Rocci; SDS, standard deviation 
score; TC, total cholesterol; TG, triglyceride; yrs, years.
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follow-up study in a large group of young adults born 
SGA who were treated during childhood with 2 years 
of GnRHa in addition to GH treatment. We show that 
2 years of GnRHa treatment in addition to GH treat-
ment does not change the metabolic health profile in 
terms of insulin sensitivity, β-cell function, body com-
position, blood pressure, serum lipid levels, and BMD. 
At 21 years of age, the GnRHa/GH group had a similar 
metabolic health profile and BMDTB as the GH-only 
and AGA groups and a higher BMDLS compared with 
the AGA group.
Our study shows that insulin sensitivity and β-cell 
function increased similarly during the first 2 years after 
GH cessation in both GnRHa-treated young adults and 
those treated with GH only. We also found that the 
GnRHa/GH group had similar FSIGT results as healthy 
young adults born AGA. A cross-sectional retrospective 
study by Lazar et al also showed no metabolic derange-
ments in GnRHa-treated female adults with CPP aged 
30 to 50 years (10). Several studies during GnRHa treat-
ment in children with CPP showed lower insulin sensi-
tivity, expressed as the homeostatic model assessment of 
insulin resistance (5-8). This might be explained by the 
difference in population as early puberty also increases 
the risk of diabetes (17). Our study shows that the add-
ition of 2 years of GnRHa treatment during childhood 
does not influence insulin sensitivity and β-cell function 
in young adults born SGA.
We found no higher prevalence of obesity and a 
similar fat mass in the GnRHa/GH-treated young adults 
compared with young adults treated with GH-only and 
healthy young adults born AGA. Several studies in chil-
dren with CPP described an increase in weight and 
BMI during GnRHa treatment, which could negatively 
influence metabolic health and cause a higher preva-
lence of obesity in adulthood (9-13). However, studies 
in children born SGA and children with CPP have also 
shown that an increase in BMI during GnRHa treat-
ment did not lead to a higher rate of obesity at AH (10, 
17, 29). Furthermore, earlier pubertal timing has been 
associated with higher BMI and a higher prevalence of 
diabetes and metabolic disease, thus it is questionable 
whether the described alterations in metabolic health are 
due to CPP rather than GnRHa treatment. Earlier pu-
bertal timing has been associated with higher BMI and 
a higher prevalence of diabetes and metabolic disease 
(30). Our results show that 2 years of GnRHa treatment 
in addition to GH treatment during childhood does not 
have an adverse effect on body composition at the age 
of 21 years. This strengthens the hypothesis that the pre-
viously reported adverse effect on body composition in 
patients with CPP could be due to the natural course of 
body composition after CPP rather than due to GnRHa 
treatment.
Our findings show that changes in SBP and DBP 
during 5  years after cessation of GH were similar in 
the GnRHa/GH and GH groups. Also, the GnRHa/
GH-treated young adults had a similar SBP and DBP 
as healthy young adults born AGA. High blood pres-
sure was only present in 3 participants of the GnRHa/
GH group, which was similar in the GH-only and AGA 
groups. Two case reports have described transient ar-
terial hypertension during GnRHa treatment (31, 32). 
Both cases showed that blood pressure returned to 
normal values after cessation of GnRHa treatment. In 
our study, none of the participants had to cease their 
GnRHa treatment because of high arterial blood pres-
sure. Our results show that in the GnRHa/GH group, 
both SBP and DBP remain well within the normal range 
and are similar to the GH group and young adults 
born AGA.
Serum lipid levels changed similarly in the GnRHa/
GH and GH groups during 5  years after GH cessa-
tion. At 21 years of age, the GnRHa/GH-treated young 
adults had similar serum TC, HDLc, LDLc, and TG 
levels as the GH-treated young adults born SGA and 
the healthy young adults born AGA. This is in line with 
other studies performed during GnRHa treatment in 
children with CPP, reporting no changes in lipid levels 
(6, 33). Our results in young adults show that serum 
lipid levels are not different due to 2 years of GnRHa 
treatment during childhood.
We have previously reported that the control group 
of young adults born SGA treated with GH-only had 
a similar metabolic health profile as untreated young 
adults born SGA (34, 35). As the results in the present 
study are similar between the GnRHa/GH and GH 
groups, it is likely that metabolic health after 2 add-
itional years of GnRHa treatment to GH treatment is 
also similar to untreated young adults born SGA.
During 5  years after GH cessation, BMDTB and 
BMADLS changed similarly in the GnRHa/GH and 
GH groups, and both groups had a similar BMDTB 
and BMADLS at 5 years after GH cessation. This is in 
line with studies in participants with CPP, describing 
a similar BMD at AH in GnRHa-treated participants 
and participant controls (9, 19, 36, 37). Our findings 
show that 2 years of GnRHa treatment in addition to 
GH treatment has no negative effects on BMD in young 
adults born SGA.
In conclusion, our longitudinal follow-up study in 
young adults born SGA during the 5 years after GH ces-
sation shows that the changes in insulin sensitivity, β-
cell function, body composition, blood pressure, serum 
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lipid levels, and BMD were unaffected by the addition 
of 2  years of GnRHa treatment for postponement of 
puberty. At 21  years of age, insulin sensitivity, β-cell 
function, body composition, blood pressure, serum lipid 
levels, and BMD were similar in GnRHa/GH-treated 
participants compared with GH-treated young adults 
born SGA and untreated young adults born AGA. These 
results show that the addition of 2  years of GnRHa 
treatment to long-term GH treatment of children short 
in stature born SGA does not have an unfavorable effect 
on metabolic health and bone mineralization at the age 
of 21 years.
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